Inov8 has provided new technology in the fight against superbugs, including MRSA, E.coli as well as Norovirus and C.diff.
Past News ReleasesRSS
Milton Keynes, United Kingdom (PRWeb UK) October 26, 2010
Representatives from Inov8, the wholly owned subsidiary of the AIM listed company Mid-States plc, recently attended a fundraising dinner in support of the CHAI, the Centre for Healthcare Associated Infections, held at the RAC Club in Pall Mall, London. Present was guest speaker ITN News reader Alistair Steward OBE who spoke on behalf of the charity.
CHAI are a research centre based in Nottingham University, focussed on helping to fight the deadly superbugs. Hospital superbugs such as MRSA and Clostridium difficile (C. diff) are killing thousands of people. Over the last decade, almost 37,000 people have died after contracting one of these two devastating infections, while C. diff alone killed more people in the UK in 2007 than all road accidents that year. Almost 37,000 people died from MRSA or C. diff between 1997 and 2007*.
Inov8 Science Ltd has developed an innovative air disinfection system, the AD, which helps to prevent the airborne spread of a wide range of viruses, bacteria and fungus. Steve Jelley, Inov8’s Vice President for Business Development who was present at the fundraising dinner explains that the company is committed to support charities such as CHAI. He said: “Inov8 has provided new technology in the fight against superbugs, including MRSA, E.coli as well as Norovirus and C.diff. The AD has become well established in a number of markets, especially the health sector and feedback from infection prevention and control staff in hospitals where units have been installed has been extremely positive.”
Steve continued: “During recent hospital trials to measure the effectiveness of the AD units, results from Sunderland City Hospital showed significant C. difficile reduction in wards where the AD units were in operation. Hereford Hospital NHS Trust also reported excellent results, with no MRSA bloodstream infections occurring during their trial period while C dificile numbers were more than halved compared with the same time the year before.”
Inov8’s AD system is a winner in the 2009 Smart Solutions Programme for the UK NHS. The system is already in use in clinics and hospitals throughout the UK, Spain, Saudi Arabia and India. It is also used in commercial offices and in government buildings worldwide.
Word count: 366
*as reported on the CHAI website.
For further information, please contact:
The Press Department
Inov8 Science Ltd
Mill Court, Featherstone Road
Wolverton, Milton Keynes MK12 5EU
Tel. +44 (0) 1908 315500
Web Site: http://www.inov8.com
Note to editors:
Inov8, The Air Disinfection Company
- INOV8 Science Limited is a wholly owned subsidiary of the AIM listed company, Mid-States PLC.
- Trials on the Inov8 AD at the Health Protection Agency's Porton Down Laboratory have demonstrated 99.999% reduction in the MS2 Coliphage (the standard surrogate used for viral tests) in addition to Staphylococcus epidermidis. Similarly, trials at Leeds University have shown dramatic levels of pathogen reduction in aerobiological chambers that were dosed with Staphylococcus Aureus and Clostridium Difficile.
- Installations at several UK hospitals have produced remarkable results, significantly reducing ward closures. To read a recent Press Release from the Hereford Hospitals NHS Trust visit: http://www.herefordhospital.nhs.uk/Portals/0/Press_Media/2009/Excellent_Results_at_Hereford_Hospitals_NHS_Trust_280909_v2.pdf
- Please also view a BBC News report at http://news.bbc.co.uk/1/hi/england/8288049.stm
- Each AD treats air space of approximately 10m x 10m x 3m in typical rooms.
- Inov8 Science Ltd has recently released a paper which provides a correlation between reduction of airborne pathogens and reduction of infection rates in hospitals. This data was presented during the HPA conference at Warwick University in September 2010. A follow up paper was presented during the 2010 Hospital Infection Society Conference, HIS2010, Liverpool, in October 2010.
- The latest information on trials and clinical outcomes from the use of the AD units is available at http://www.inov8.com
- CHAI, Centre for Healthcare Associated Infections are based in Nottingham University (http://www.hcai.nottingham.ac.uk)
- Nottingham University has an international reputation and a critical mass of basic research activity on four bacterial healthcare associated infections
--Clostridium difficile; E.coli; MRSA and other staphylococci; and Pseudomonas aeruginosa
- Nottingham University has world leading expertise in the development of genetic tools for Clostridia.